Winchester – Winchester District Memorial Hospital (WDMH) is pleased to partner with the North Dundas Medical Clinic and Boehringer Ingelheim (Canada) Ltd. on a new quality improvement project. The goal is to enhance care for heart failure patients with and without diabetes.
Despite its prevalence in Canada, research indicates that heart failure is still under-recognized. When recognized, it is sometimes poorly managed. “Approaches to care can be unorganized between health care providers, resulting in significant variation in treatment and management of these patients,” explains Dr. Mohamed Gazarin, WDMH’s Chief Research Officer.
Over the next year, WDMH and North Dundas Medical Clinic will evaluate how the treatment guidelines are followed when providing care for heart failure patients with and without diabetes. The data will help to create a heart failure pathway that can be used at both organizations. The result will be more specialized and better-defined care for these patients in our local communities.
Dr. Mary Naciuk, a family physician at North Dundas Medical Clinic, adds that as many as one- third of heart failure patients also have diabetes. “Heart failure patients with diabetes may be less likely to receive the necessary appropriate therapies. We want to change that.”
The project is supported in part by Boehringer Ingelheim (Canada) Ltd., a research-driven pharmaceutical company, focused on developing innovative therapies. “We want to help advance patient care and we are excited to work with this innovative team. This project underscores our dedication to delivering innovative solutions that serve current and future healthcare needs,” notes Healthcare Affairs Manager, James Thompson.
For more information about WDMH’s research program, please visit www.wdmh.on.ca/reserch or contact Dr. Mohamed Gazarin at 613-774-2420 ext. 6226 or firstname.lastname@example.org. Mohamed Gazarin at 613-774-2420 x6226 or email@example.com
Featured photo: (l-r): Mikyla Lennard, Clinical Manager; Cholly Boland, WDMH CEO; Dr. Mohamed Gazarin, WDMH Chief Research Officer; Dr. Mary Naciuk, North Dundas Medical Centre; and James Thompson, Healthcare Affairs Manager, Boehringer Ingelheim (Canada) Ltd.